Seropositivity and epidemiology of human parechovirus types 1, 3, and 6 in Japan

2016 ◽  
Vol 144 (16) ◽  
pp. 3451-3460 ◽  
Author(s):  
K. WATANABE ◽  
C. HIROKAWA ◽  
T. TAZAWA
Keyword(s):  
Neutralizing Antibodies ◽  
Respiratory Diseases ◽  
Clinical Symptoms ◽  
Age Groups ◽  
Gastrointestinal Symptoms ◽  
Neutralizing Antibody ◽  
Young Infants ◽  
Antibody Titres ◽  
Type 3 ◽  
Increased Susceptibility

SUMMARYHuman parechoviruses (HPeVs) mainly infect young children, causing mild gastrointestinal and respiratory diseases; however, HPeV type 3 (HPeV3) causes severe systemic diseases in young infants. To clarify the characteristics of HPeV infections from the aspects of seropositivity and epidemiology, we measured neutralizing antibody titres against HPeVs in individuals of in different age groups and isolated HPeVs from various clinical specimens in Niigata, Japan. The seropositivity to HPeV1, 3, and 6 was higher in older age group. HPeV1 and HPeV6 seropositivities were maintained in adults, whereas HPeV3 seropositivity was significantly lower in subjects aged >40 years (P < 0·001, P = 0·003). This result suggests that adults have increased susceptibility to HPeV3 as they lack neutralizing antibodies against HPeV3. Of the HPeV isolates, HPeV1 and HPeV6 frequently caused gastrointestinal symptoms. Moreover, gastroenteritis patients with HPeV1 and HPeV6 were mainly aged 6 months–1 year and ⩾2 years, respectively. In contrast, only HPeV3 was isolated from neonates and young infants with sepsis or sepsis-like syndrome, often with respiratory symptoms. These results suggest that clinical symptoms are clinically related to HPeV genotype and patients’ age.

scholarly journals Human enterovirus infection in stray dogs. Some aspects of interest to public health

1996 ◽  
Vol 38 (2) ◽  
pp. 157-161 ◽  
Author(s):  
Eliseu Alves Waldman ◽  
Regina C. Moreira ◽  
Sueli G. Saez ◽  
Denise F.C. Souza ◽  
Rita de C.C. Carmona ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Neutralizing Antibody ◽  
Human Enterovirus ◽  
Poliovirus Type ◽  
Stray Dogs ◽  
Wild Poliovirus ◽  
Antibody Titres ◽  
Global Eradication ◽  
Type 3 ◽  
Echovirus Type

To investigate the possible role of domestic animals as reservoirs of human enteroviruses, we studied 212 stray dogs captured in different areas of the municipality of São Paulo. The captured animals were divided into 19 groups of 10 to 20 dogs each; faeces of 126 of the 212 dogs were processed for enterovirus isolation. The following viruses were isolated from 12 dogs: poliovirus type 1 (2 dogs), poliovirus type 3 (1 dog), echovirus type 7 (8 dogs) and echovirus type 15 (1 dog). Of the 12 infected animals, four had specific homotypic neutralizing antibody titres > 16. All 212 animals were tested for the presence of neutralizing antibodies to human enteroviruses. The frequency of neutralizing antibodies present in titres of > 16 was 10.3%, 3,8% and 4.3% for vaccinal prototypes of polioviruses 1, 2 and 3 respectively; 1,9%, 1.4% and 1.5% for wild prototypes of the same viruses, 11.3% for echovirus 7, and 2.4% for echovirus 15. The proportion of dogs with neutralizing antibodies varied with the virus studied. Some indication of the susceptibility of dogs to infection with human enteroviruses was demonstrated, and the importance of this fact for the Plan for Global Eradication of the Wild Poliovirus is discussed.

scholarly journals Safety and Immunogenicity Evaluation of Inactivated whole-virus-SARS-COV-2 As Emerging Vaccine Development In Egypt

2021 ◽  
Author(s):  
Amani A. Saleh ◽  
Mohamed A. Saad ◽  
Islam Ryan ◽  
Magdy Amin ◽  
Mohamed I. Shindy ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Vaccine Development ◽  
Clinical Symptoms ◽  
Neutralizing Antibody ◽  
Positive Development ◽  
Virus Challenge ◽  
Cell Monolayers ◽  
Transmission Electron ◽  
Dose Concentration ◽  
Antibody Titers

AbstractThe current worldwide pandemic COVID-19 is causing severe human health problems, with high numbers of mortality rates and huge economic burdens that require an urgent demand for safe, and effective and vaccine development. Our study was the first trail to development and evaluation of safety and immune response to inactivated whole SARS-COV-2 virus vaccine adjuvanted with aluminium hydroxide. We used characterized SARS-COV-2 strain, severe acute respiratory syndrome coronavirus 2 isolates (SARS-CoV-2/human/EGY/Egy-SERVAC/2020) with accession numbers; MT981440; MT981439; MT981441; MT974071; MT974069 and MW250352 at GenBank that isolated from Egyptian patients SARS-CoV-2-positive. Development of the vaccine was carried out in a BSL - 3 facilities and the immunogenicity was determined in mice at two doses (55µg and 100µg per dose). All vaccinated mice were received a booster dose 14 days post first immunization. Our results demonstrated distinct cytopathic effect on the vero cell monolayers induced through SARS-COV-2 propagation and the viral particles were identified as Coronaviridae by transmission electron microscopy. SARS-CoV-2 was identified by RT-PCR performed on the cell culture. Immunogenicity of the developed vaccine indicated the high antigen-binding and neutralizing antibody titers, regardless the dose concentration, with excellent safety profiles.However, no deaths or clinical symptoms in mice groups. The efficacy of the inactivated vaccine formulation was tested by wild virus challenge the vaccinated mice and detection of viral replication in lung tissues. Vaccinated mice recorded complete protection from challenge infection three weeks post second dose. SARS-COV-2 replication was not observed in the lungs of mice following SARS-CoV-2 challenge, regardless of the level of serum neutralizing antibodies. This finding will support the future trials for evaluation an applicable SARS-CoV-2 vaccine candidate.

scholarly journals Trends in Poliovirus Seroprevalence in Kano State, Northern Nigeria

2018 ◽  
Vol 67 (suppl_1) ◽  
pp. S103-S109
Author(s):  
Harish Verma ◽  
Zubairu Iliyasu ◽  
Kehinde T Craig ◽  
Natalie A Molodecky ◽  
Utibeabasi Urua ◽  
...  
Keyword(s):  
Old Age ◽  
Age Groups ◽  
Significant Risk ◽  
Immunization Coverage ◽  
Neutralizing Antibody ◽  
Age Group ◽  
Parental Consent ◽  
Population Immunity ◽  
Antibody Titres ◽  
The Impact

Abstract Background Kano state has been a protracted reservoir of poliovirus in Nigeria. Immunity trends have been monitored through seroprevalence surveys since 2011. The survey in 2015 was, in addition, intended to assess the impact of use of inactivated poliovirus vaccine (IPV). Methods It was a health facility based seroprevalence survey. Eligible children aged 6-9, 12-15 and 19-22 months of age brought to the paediatrics outpatient department of Murtala Mohammad Specialist Hospital between 19 October and 6 November 2015, were screened for eligibility. Eligible children were enrolled after parental consent, history taken, physical examination conducted, and a blood sample collected to test for neutralizing antibody titres against the three poliovirus serotypes. Results Overall, 365 results were available in the three age groups. In the 6-9-month-old age group, the seroprevalence was 73% (95% confidence interval [CI] 64-80%), 83% (95% CI 75-88%), and 66% (95% CI 57-73%) for serotypes 1, 2, and 3, respectively. In the 12-15- and 19-22-month-old age groups, seroprevalence was higher but still remained <90% across serotypes. Seroprevalence to serotypes 1 and 3 in 2015 was similar to 2014; however, for serotype 2 there was a significant improvement. IPV received in supplemental immunization activities was found to be a significant predictor of seropositivity among 6-9-month-old infants for serotypes 1 and 2. Conclusions Seroprevalence for serotypes 1 and 3 remains low (<80%) in 6-9-month-olds. This poses a significant risk for poliovirus spread if reintroduced into the population. Efforts to strengthen immunization coverage are imperative to secure and sustain high population immunity.

scholarly journals Epidemic Kerato-Conjunctivitis—An Adenovirus Infection

1958 ◽  
Vol 56 (1) ◽  
pp. 101-107 ◽  
Author(s):  
R. G. Sommerville
Keyword(s):  
Technical Assistance ◽  
Specific Effect ◽  
Neutralizing Antibody ◽  
Adenovirus Type ◽  
Serological Examination ◽  
Central Public Health ◽  
Number Of Patients ◽  
Antibody Titres ◽  
Virus Research ◽  
Type 3

Two strains of adenovirus Type 3 were isolated from fifty-nine patients suffering from epidemic kerato-conjunctivitis. Serological examination of a further group of fifty-nine patients revealed that neutralizing antibody to adenovirus Type 8 usually developed when the duration of the disease exceeded 14 days, and that at the same time a smaller number of patients also developed low titre neutralizing antibody to Type 3 adenovirus. From the evidence presented it is suggested that adenovirus Type 8 was the infecting organism in the majority of cases, and that when neutralizing antibody to Types 3, 6 or 7 adenovirus was present this probably represented a non-specific effect of stimulation by a heterotypic strain of adenovirus. Insignificant antibody titres by C.F. tests were frequently associated with high titres of neutralizing antibody hi the late convalescent phase of the illness.I would like to express my gratitude for assistance in obtaining material for the investigation to the following clinicians: Dr J. Winning, Dr J. Marshall, Dr A. Mellick and Dr A. M. W. Thomson of the Eye Infirmary, Glasgow, and to Dr E. McNaught of the Ophthalmic Institution, Glasgow; for supplies of adenovirus seed to Dr B. E. Andrews, Central Public Health Laboratory, Colindale and Dr D. A. J. Tyrrell, Virus Research Laboratory, Sheffield; and for technical assistance to C. McLean, F.I.M.L.T., H. G. Carson, F.I.M.L.T. and J. Kerr.

scholarly journals The feasibility of convalescent plasma therapy in severe COVID- 19 patients: a pilot study

2020 ◽  
Author(s):  
Kai Duan ◽  
Bende Liu ◽  
Cesheng Li ◽  
Huajun Zhang ◽  
Ting Yu ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Clinical Symptoms ◽  
Antiviral Agents ◽  
Neutralizing Antibody ◽  
Optimal Dose ◽  
Plasma Therapy ◽  
Reactive Protein ◽  
Antibody Titers ◽  
Novel Coronavirus ◽  
High Level

AbstractCurrently, there are no approved specific antiviral agents for 2019 novel coronavirus disease (COVID-19). In this study, ten severe patients confirmed by real-time viral RNA test were enrolled prospectively. One dose of 200 mL convalescent plasma (CP) derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to maximal supportive care and antiviral agents. The primary endpoint was the safety of CP transfusion. The second endpoints were the improvement of clinical symptoms and laboratory parameters within 3 days after CP transfusion. The median time from onset of illness to CP transfusion was 16.5 days. After CP transfusion, the level of neutralizing antibody increased rapidly up to 1:640 in five cases, while that of the other four cases maintained at a high level (1:640). The clinical symptoms were significantly improved along with increase of oxyhemoglobin saturation within 3 days. Several parameters tended to improve as compared to pre-transfusion, including increased lymphocyte counts (0.65×109/L vs. 0.76×109/L) and decreased C-reactive protein (55.98 mg/L vs. 18.13 mg/L). Radiological examinations showed varying degrees of absorption of lung lesionswithin 7 days. The viral load was undetectable after transfusion in seven patients who had previous viremia. No severe adverse effects were observed. This study showed CP therapy was welltolerated and could potentially improve the clinical outcomes through neutralizing viremia in severe COVID-19 cases. The optimal dose and time point, as well as the clinical benefit of CP therapy, needs further investigation in larger well-controlled trials.Significance StatementCOVID-19 is currently a big threat to global health. However, no specific antiviral agents are available for its treatment. In this work, we explored the feasibility of convalescent plasma (CP) transfusion to rescue severe patients. The results from 10 severe adult cases showed that one dose (200 mL) of CP was welltolerated and could significantly increase or maintain the neutralizing antibodies at a high level, leading to disappearance of viremia in 7 days. Meanwhile, clinical symptoms and paraclinical criteria rapidly improved within 3 days. Radiological examination showed varying degrees of absorption of lung lesions within 7 days. These results indicate that CP can serve as a promising rescue option for severe COVID-19 while the randomized trial is warranted.

scholarly journals Safety and immunogenicity evaluation of inactivated whole-virus-SARS-COV-2 as emerging vaccine development in Egypt

2021 ◽  
Author(s):  
Amani A Saleh ◽  
Mohamed A Saad ◽  
Islam Ryan ◽  
Magdy Amin ◽  
Mohamed I Shindy ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Vaccine Development ◽  
Clinical Symptoms ◽  
Neutralizing Antibody ◽  
Positive Development ◽  
Effective Vaccine ◽  
Inactivated Vaccine ◽  
Virus Challenge ◽  
Transmission Electron ◽  
Dose Concentration

Abstract Background Current worldwide pandemic COVID-19 with high numbers of mortality rates and huge economic problems require an urgent demand for safe and effective vaccine development. Inactivated SARS-CoV2 vaccine with alum. Hydroxide can play an important role in reducing the impacts of the COVID-19 pandemic. In this study, vaccine efficacy was evaluated through the detection of the neutralizing antibodies that protect mice from challenge with SARS-CoV 2 three weeks after the 2nd dose. We conclude that the vaccine described here has safety and desirable properties, and our data support further development and plans for clinical trials. Methods Characterized SARS-COV-2 strain, severe acute respiratory syndrome coronavirus 2 isolates (SARS-CoV-2/human/EGY/Egy-SERVAC/2020) with accession numbers; MT981440; MT981439; MT981441; MT974071; MT974069, and MW250352 at GenBank were isolated from Egyptian patients SARS-CoV-2-positive. Development of inactivated vaccine was carried out in a BSL—3 facilities and the immunogenicity was determined in mice at two doses (55 μg and 100 μg per dose). Results The distinct cytopathic effect (CPE) induced by SARS-COV-2 propagation on Vero cell monolayers and the viral particles were identified as Coronaviridae by transmission electron microscopy and RT-PCR on infected cells cultures. Immunogenicity of the developed vaccine indicated the high antigen-binding and neutralizing antibody titers, regardless of the dose concentration, with excellent safety profiles and no deaths or clinical symptoms in mice groups. The efficacy of the inactivated vaccine formulation was tested by the wild virus challenge of the vaccinated mice and viral replication detection in lung tissues. Conclusions Vaccinated mice recorded complete protection from challenge infection via inhibition of SARS-COV-2 replication in the lung tissues of mice following virus challenge, regardless of the level of serum neutralizing antibodies. This finding will support future trials for the evaluation of an applicable SARS-CoV-2 vaccine candidate.

scholarly journals A survey of measles antibodies in different populations

1964 ◽  
Vol 62 (1) ◽  
pp. 45-51 ◽  
Author(s):  
Gillian Tilden Smith
Keyword(s):  
General Practitioners ◽  
Technical Assistance ◽  
Age Groups ◽  
Serum Samples ◽  
Past Infection ◽  
Rapid Acquisition ◽  
Young Infants ◽  
Measles Antibodies ◽  
Antibody Titres ◽  
Different Populations

A survey of serum samples from all age groups in the population has shown a rapid acquisition of antibody between the ages of 1 and 6 years which reaches a plateau in concentration and does not disappear later.The concentration of antibody in cord serum may be four or more times greater than that in the mother's serum.Presence or absence of a record of past infection by measles is not necessarily reflected by the titre of antibody in the serum.Low antibody titres in very young infants may be due to an imperfectly developed antibody producing mechanism.The author gratefully acknowledges the assistance of all those who made this survey possible. In particular, she is indebted to Dr G. I. Watson of the College of General Practitioners and his colleagues (see list) for their help in the collection of so many of the serum samples, and to Mr D. A. Bamgboye for his excellent technical assistance.

scholarly journals The effect of vaccination regimen on the transfer of foot and mouth disease antibodies from the sow to her piglets

1984 ◽  
Vol 93 (1) ◽  
pp. 123-131 ◽  
Author(s):  
M. J. Francis ◽  
L. Black
Keyword(s):  
Neutralizing Antibodies ◽  
Foot And Mouth Disease ◽  
Neutralizing Antibody ◽  
Mouth Disease ◽  
Oil Emulsion ◽  
Fmd Virus ◽  
Significant Difference ◽  
Foot And Mouth ◽  
Antibody Titres ◽  
Antibody Class

SUMMARYFour groups of pregnant sows were inoculated with type O1 foot and mouth disease (FMD) oil emulsion vaccine at various times before farrowing and samples of the sow's serum, colostrum and milk, and piglet's serum, collected during the first week after farrowing, were analysed for FMD virus neutralizing activity.No FMD neutralizing antibodies were detectable in the piglets serum at birth but they were present 1·5 h after suckling and peak titres were reached 1–3 days later. There was no significant difference between the antibody titres of colostrum samples collected from different teats at farrowing. However, similar samples collected 3 days later showed significant (P < 0·005) fore to hind variation. The principal FMD virus neutralizing antibody class present in the sow's serum at farrowing and in their 3-day-old piglets was governed by the inoculation schedule employed. When the last vaccinations were given ≃ 30 days before farrowing (dbf) the predominant FMD virus neutralizing class was IgG. However, when the sows were vaccinated only ≃ 12 dbf the predominant class was IgM. A significant correlation was observed between the sow's serum titres and colostrum titres at farrowing (r = 0·90), and also between sows colostrum titres at farrowing and their 3-day-old piglets serum titres (r = 0·99).

Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study

2009 ◽  
Vol 15 (12) ◽  
pp. 1481-1488 ◽  
Author(s):  
Claudia Gneiss ◽  
Pia-Maria Koudouovoh-Tripp ◽  
Stefan Ropele ◽  
Thaddäus Gotwald ◽  
Rainer Ehling ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Interferon Beta ◽  
Previous Treatment ◽  
Neutralizing Antibody ◽  
High Dose ◽  
Continuous Therapy ◽  
High Dose Methylprednisolone ◽  
Antibody Titres ◽  
Antibody Positivity ◽  
To Receive

Neutralizing antibodies against interferon-beta are associated with a reduction of the efficacy of this drug. Continuing treatment leads to a decline or even loss of neutralizing antibodies over years. No strategies are currently available to shorten the period of neutralizing antibody positivity. The objective of this study was to investigate the effect of switching between high and low immunogenic interferon-beta products on neutralising antibody titres. Twenty-four patients treated with the subcutaneously administered interferon-beta 1b or 1a and high titres of neutralizing antibodies were included. At baseline interferon-beta therapy was interrupted for 3 months and two pulses of high dose methylprednisolone were applied. Patients were then randomized to receive either the previous interferon-beta preparation or the low immunogenic intramuscular interferon-beta 1a. The primary end-point was the change of neutralizing antibody titres 12 months after randomization. Twelve patients were switched to interferon-beta 1a intramuscularly and 12 patients remained on previous treatment. Median neutralizing antibody titres were 846 NU at baseline and 196 NU at the end of the study. The median change of neutralizing antibody titres did not differ significantly between therapy switchers and non-switchers. Baseline and final neutralizing antibody titres correlated significantly. In conclusion, neither switching nor continuous therapy with any subcutaneous interferon-beta preparation significantly changed neutralizing antibody titres.

scholarly journals Zika seroprevalence declines and neutralizing antibodies wane in adults following outbreaks in French Polynesia and Fiji

eLife ◽  
2020 ◽  
Vol 9 ◽  
Author(s):  
Alasdair D Henderson ◽  
Maite Aubry ◽  
Mike Kama ◽  
Jessica Vanhomwegen ◽  
Anita Teissier ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Neutralizing Antibody ◽  
French Polynesia ◽  
Significant Decline ◽  
High Seroprevalence ◽  
Zikv Infection ◽  
Cross Sectional ◽  
Before And After ◽  
Antibody Titres

It has been commonly assumed that Zika virus (ZIKV) infection confers long-term protection against reinfection, preventing ZIKV from re-emerging in previously affected areas for several years. However, the long-term immune response to ZIKV following an outbreak remains poorly documented. We compared results from eight serological surveys before and after known ZIKV outbreaks in French Polynesia and Fiji, including cross-sectional and longitudinal studies. We found evidence of a decline in seroprevalence in both countries over a two-year period following first reported ZIKV transmission. This decline was concentrated in adults, while high seroprevalence persisted in children. In the Fiji cohort, there was also a significant decline in neutralizing antibody titres against ZIKV, but not against dengue viruses that circulated during the same period.

Sign in / Sign up

Export Citation Format

Share Document